VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Inclusion Criteria

• •Diagnosis of CLL per the WHO classification
• •At least 18 years of age
• •Lack of a complete response after receiving ibrutinib for \> 1 year OR presence of known ibrutinib resistance mutation
• •Actively receiving ibrutinib at either 420 mg (patients enrolled to the escalation arm) or at a stable dose for at least 2 months prior to starting study treatment (patients enrolled to the expansion arm)